title: How long can we leave patients with pulmonary arterial hypertension on oral drug monotreatment?
authors.forename: Aiko
authors.initials: A
authors.lastname: Ogawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Matsubara
mesh_terms: D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D011687:Purines / Q000008:administration & dosage; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000008:administration & dosage*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate